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ABSTRACT 
Antimicrobial Susceptibility Testing in Host-Mimicking Media versus Standard 
Testing Media 
by 
Geneva Kathyran Tripp 
 
Antibiotic resistance has emerged as a serious threat to society and is responsible 
for at least 2 million illnesses each year. A common contribution to the spread of 
antibiotic resistance is the incorrect use of antibiotics. Prescription of the correct 
drug increases the chance of completely eliminating the infection early on and 
lowers the risk of selecting for resistant strains. Antimicrobial susceptibility testing 
(AST) results guide physicians in their decision of which antibiotic to prescribe. 
Current AST is carried out in a standardized manner in vitro which unfortunately 
does not consistently represent the outcome in the host environment. Improvements 
in AST methods must be implemented in order to provide a more accurate 
prediction of treatment outcome. We have introduced a novel approach to 
performing AST by substituting the standard media with host-mimicking media. We 
found in several cases that when host-mimicking media is used for testing, the 
susceptibility or resistance of a strain to a drug can be significantly altered and even 
change the prediction of whether drug will succeed or fail in the host. We also 
observed treatment outcomes in vivo that were consistent with the susceptibility 
profiles obtained with host-mimicking media but inconsistent with the susceptibility 
profiles obtained with standard media. Further, the addition of sodium bicarbonate 
(NaHCO3) to standard testing medium often resulted in the same susceptibility 
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profiles that were obtained with host-mimicking media and linked to in vivo 
treatment outcomes. This indicates that the presence of certain signaling molecules 
in testing media could be a simple change that improves the accuracy of AST. 
Lastly, we investigated the role of fetal bovine serum (FBS) as an extracellular 
signal that contributed to changes in susceptibility profiles. Overall, these findings 
emphasize the importance of recapitulating the host environment to obtain more 
accurate AST results, correct prescription of drugs, and in turn reduced cases of 
antibiotic resistance. 
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Chapter 1: Introduction 
1.1 The Rise of Antibiotic Resistance 
Long before the existence of modern antibiotics and the impact of human 
industrialization on the environment, microorganisms developed abilities to 
biosynthesize chemicals that were toxic to other bacteria, thus enabling their 
survival in the highly diverse and competitive natural environments such as soil and 
water (Finley et al., 2013). Along with these capabilities and the selective pressure 
to withstand these toxins in the microbial environment came the evolution of modes 
of resistance, by genetic mutation or acquisition of new DNA, to provide a 
competitive advantage for resistant bacteria (Allen et al., 2010; McManus, 1997). 
Billions of years later, beginning with the discovery of penicillin by Alexander 
Fleming in 1928, modern medicine was transformed and humans entered the 
modern era of antibiotics (Sengupta, Chattopadhyay, & Grossart, 2013). However, 
the success in controlling bacterial infections with newly developed antibiotics was 
short-lived and the emergence of resistant strains continued. In the present day, the 
antibiotic resistance crisis is growing and is a result of the overuse and incorrect 
prescription of drugs combined with the lack of development of new antibiotics 
(Ventola, 2015). In fact, there is a direct relationship between antibiotic consumption 
and the emergence of resistant bacteria strains ("The antibiotic alarm," 2013). This 
is because treatment with antibiotics speeds up the selection for resistant bacteria 
by removing drug-sensitive bacteria and leaving behind resistant bacteria. 
Additionally, treating bacterial infections with the wrong antibiotic exposes the strain 
to sub-inhibitory antibiotic doses. Not only can this cause changes in gene 
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expression that impact virulence, but it also promotes antibiotic resistance via 
increased horizontal gene transfer and mutagenesis (Sengupta et al., 2013; 
Viswanathan, 2014). It is crucial to understand the mechanisms by which bacteria 
can become resistant so that more prudent decisions can be made regarding the 
prescription of antibiotics. 
1.2 Mechanisms of Antibiotic Resistance 
Antibiotic resistance can be acquired by mutation of existing DNA or by uptake 
of foreign DNA. In addition to spontaneous mutations that cause resistance, many 
of the genes that are known to enable antibiotic resistance are found on 
transposons, integrons, or plasmids which can be transferred to other bacteria 
(Allen et al., 2010). The most common way that bacteria acquire antibiotic 
resistance is horizontal gene transfer, which results in the movement of resistance 
genes between bacterial species as well as the acquiring of resistance mechanisms 
in bacteria that were previously harmless (Davies & Davies, 2010; Finley et al., 
2013). The ability to acquire DNA molecules by natural transformation is conserved 
among a wide range of bacteria, indicating that this genetic trait is functionally 
important for survival in the environment (Thomas & Nielsen, 2005).  
There are several mechanisms by which the transfer of genetic material 
enables bacteria to become resistant to an antibiotic. The bacteria may obtain 
genes encoding enzymes that destroy the antibacterial agent, such as beta-
lactamase enzymes which provide multi-resistance to beta-lactam antibiotics like 
penicillins and Cephalosporins (McManus, 1997; Tenover, 2006). Additionally, 
bacteria may acquire efflux pumps that force the antibiotic out of the cell (Tenover, 
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2006). Bacteria may also obtain several genes that each play a role in a metabolic 
pathway to alter the bacterial cell wall and prevent the antimicrobial agent from 
binding. Further, mutations that downregulate porin genes limit the access of 
antibiotics into the cell. In each of these cases the bacteria prevent the antimicrobial 
agent from reaching its target and exerting its effect. 
There are also multiple mechanisms by which spontaneous mutations in 
bacteria can lead to antibiotic resistance. First, these mutations can modify or 
eliminate the binding site of the target protein such that the drug can no longer 
bind(Tenover, 2006). Second, a mutation can either upregulate pumps that expel 
the drug from the cell or downregulate an outer membrane protein channel that is 
required for the drug to enter the cell. Third, a mutation can upregulate the 
production of enzymes that inactivate the antimicrobial agent. Similar to the transfer 
of genetic material, the mechanisms of spontaneous mutations enable antibiotic 
resistance by preventing the drug from reaching its target. 
No matter the mechanism, the use of antibiotics selects for antibiotic 
resistance by killing the susceptible strains and allowing the newly resistant strains 
to survive and reproduce. To gain better control of the rapid spread of antibiotic 
resistance, it is necessary to implement effective screening methods that will 
correctly determine the optimal antibiotic for treatment. By prescribing the correct 
compounds we reduce instances of treatment failure and in turn prevent the 
selection and spread of resistant bacteria. 
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1.3 Antimicrobial Susceptibility Testing and Clinical Breakpoints 
Antimicrobial susceptibility testing (AST) is a standardized method performed in 
vitro to determine the most effective antibiotic(s) to prescribe for a bacterial 
infection. Due to the many variables that affect AST protocols, the World Health 
Organization (WHO) standardized these methods across the world in 1950 (Wheat, 
2001). The Clinical and Laboratory Standards Institute (CLSI) in the United States 
then developed AST guidelines which cover specifications regarding the testing 
media, incubation conditions, inoculum density, and antibiotic dilution ranges so that 
AST can be performed in a standardized manner across laboratory settings (Clinical 
and Laboratory Standards Institute, 2012a, 2014). 
The in vitro AST methods begin with a bacterial isolate that is grown in the 
standard testing medium, Mueller Hinton Broth (MHB), then diluted to a specific cell 
density and exposed to a range of 2-fold serial dilutions of a particular drug. The 
“Minimum Inhibitory Concentration” (MIC) is the lowest concentration of drug at 
which no cell growth is observed after the incubation period. These results are then 
interpreted using clinical breakpoints that have been established by various 
organizations and the MIC values are categorized as “Susceptible”, “Intermediate”, 
or “Resistant” (Turnidge & Paterson, 2007). A “Susceptible” MIC implies that the 
bacterial isolate will be inhibited by a recommended dosage of an antimicrobial 
agent. An “Intermediate” MIC indicates that the antibiotic may or may not work and 
should be prescribed with caution and only when there are no other available 
therapeutic options. A “Resistant” MIC implies that the antimicrobial agent will likely 
fail in vivo. The purpose of clinical breakpoints is to enable clinical microbiology 
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laboratories to communicate AST results to the prescribers in a way that will 
optimize antibiotic selection for the treatment of a bacterial infection. However, the 
establishment and use of clinical breakpoints is under the assumption that the in 
vitro MIC is representative of in vivo susceptibility.  
Although the standardization of AST is cost effective and allows for 
reproducibility of results across laboratories, there are underlying flaws to these 
methods that can ultimately result in the incorrect prescription of antibiotics. The 
misuse of antibiotics not only contributes to antibiotic resistance through the 
selection of resistant strains, but it can also result in the spread of infection and loss 
of a patient’s life. Therefore, it is absolutely necessary to consider modifications to 
the traditional AST that may improve the accuracy of test results and provide a 
higher rate of treatment success. 
1.4 Using Host-Mimicking Media for in vitro Testing 
Bacteria utilize environmental signals to alter gene expression and adapt to their 
changing environments. One mechanism for this is to use a two-component 
regulatory system (TCRS), composed of an extracellular sensor and an intracellular 
transcription factor (Gunn, 2008; Mekalanos, 1992). In the presence of a particular 
environmental cue, the extracellular sensor turns “on” and activates the intracellular 
transcription factor typically by phosphorylation. This active transcription factor then 
activates or represses the expression of specific genes. PhoPQ is an example of a 
TCRS in Salmonella that is activated by low magnesium and mildly acidic pH in the 
environment and in turn induces changes in gene expression that enable survival 
within host macrophages (Groisman, 2001; Gunn & Richards, 2007; Miller, Kukral, 
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& Mekalanos, 1989). Additionally, there are many other environmental cues – 
temperature, CO2, iron, and other compounds – that regulate virulence factors by 
playing a role in the highly complex signal transduction systems that bacteria have 
developed. Further, IVET (in vivo expression technology) was developed to identify 
genes expressed during infection (Mahan, Slauch, & Mekalanos, 1993). This 
system uses plasmid libraries containing a functional in vivo activated promotor 
fused to a gene required for growth in vivo, such that only strains that have taken up 
this plasmid will grow in the host. Identification of the promoters activated in vivo 
enables us to determine the downstream genes regulated by these promoters. This 
information proves useful in creating a media that will mimic the in vivo environment 
by activating virulence factors that are expressed in vivo. For example, a pH 5.5 
media low in phosphate and magnesium was shown to activate the PhoPQ gene 
regulator and, as described previously (Gunn, 2008; Mekalanos, 1992), stimulate 
expression of genes necessary for growth within the host cells. Thus, it is clear that 
bacteria differentially express virulence genes depending on the media they are 
grown in.  
While the established AST methods performed in vitro are often valuable and 
lead to correct antibiotic prescription and successful treatment of bacterial 
infections, this is not always the case. Gene expression in bacteria is highly 
regulated by the extracellular environment such that a strain may have altered 
susceptibility to a particular drug when grown in a different media. Therefore, it is 
incorrect to assume that the rich and universal testing media, MHB, closely 
represents the host environment and will provide accurate MIC values in every 
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case. This disconnect between in vitro testing and the true in vivo susceptibility 
leads to treatment with antibiotics that will not clear the infection as well as the 
ruling out of antibiotics that are quite capable of clearing the infection. By performing 
AST with strains grown in host-mimicking media, we can create an environment that 
better represents the body. We hypothesize that bacteria grown in host-mimicking 
media, specifically those grown in serum-like media, will demonstrate altered 
susceptibility to antibiotics compared to those grown in the standard MHB.   
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Chapter 2: Correcting a Fundamental Flaw in the Paradigm for Antimicrobial 
Susceptibility Testing† 
†This chapter contains excerpts, reproduced with permission, from Ersoy SC et 
al. (2017) Correcting a Fundamental Flaw in the Paradigm for Antimicrobial 
Susceptibility Testing. EBioMedicine. (20): 173-181. 
Summary of Contributions to Work 
Assisted in the screening process to determine Minimum Inhibitory 
Concentration (MIC) of antibiotics for strains grown in host-mimicking media. 
Contributed significantly to MIC testing for all antibiotics and strains in media with 
and without sodium bicarbonate. 
Abstract 
The emergence and prevalence of antibiotic-resistant bacteria are an increasing 
cause of death worldwide, resulting in a global ‘call to action’ to avoid receding into 
an era lacking effective antibiotics. Despite the urgency, the healthcare industry still 
relies on a single in vitro bioassay to determine antibiotic efficacy. This assay fails to 
incorporate environmental factors normally present during host-pathogen 
interactions in vivo that significantly impact antibiotic efficacy. Here we report that 
standard antimicrobial susceptibility testing (AST) failed to detect antibiotics that are 
in fact effective in vivo; and frequently identified antibiotics that were instead 
ineffective as further confirmed in mouse models of infection and sepsis. Notably, 
AST performed in media mimicking host environments succeeded in identifying 
specific antibiotics that were effective in bacterial clearance and host survival, even 
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though these same antibiotics failed in results using standard test media. Similarly, 
our revised media further identified antibiotics that were ineffective in vivo despite 
passing the AST standard for clinical use. Supplementation of AST medium with 
sodium bicarbonate, an abundant in vivo molecule that stimulates global changes in 
bacterial structure and gene expression, was found to be an important factor 
improving the predictive value of AST in the assignment of appropriate therapy. 
These findings have the potential to improve the means by which antibiotics are 
developed, tested, and prescribed. 
2.1 Introduction 
Multidrug-resistant bacteria are a leading cause of death worldwide and 
undermine advances in medical and surgical management of multiple diseases 
(Centers for Disease Control and Prevention, 2013; World Health Organization, 
2014). Despite this urgent threat (U.S. White House, 2015; World Health Assembly, 
2014), the healthcare industry continues to rely on a single bioassay standardized in 
1961 by the World Health Organization to determine antibiotic efficacy (World 
Health Organization, 1961). Although this bioassay has been immensely valuable 
for several decades, it is fundamentally flawed because it is based largely on in vitro 
efficacy, and often fails to correlate with patient outcome (Kubicek-Sutherland et al., 
2015). Reliance on this bioassay may have inadvertently contributed to the rise in 
multidrug-resistant bacteria because it disqualifies efficacious compounds (Diene & 
Rolain, 2014). 
A key parameter that guides decisions regarding antimicrobial therapy is the 
clinical breakpoint: the antimicrobial concentrations that are used to define isolates 
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as susceptible (“S”), intermediate (“I”), or resistant (“R”) (Clinical and Laboratory 
Standards Institute, 2012a; European Committee on Antibiotic Susceptibility 
Testing, 2014). Clinical breakpoints are established by a sequential procedure. (1) 
In vitro efficacy is assessed by standard antimicrobial susceptibility testing (AST), 
which determines the minimum inhibitory concentration (“MIC”) of antibiotics to 
which a pathogen is sensitive. (2) Pharmacokinetic/pharmacodynamic (PK/PD) 
parameters are measured in animals (dosing, distribution, localization). (3) 
Efficacy/toxicity is established in animals for a limited number of model pathogens. 
(4) Dosing protocols are validated with limited patient clinical data. Unfortunately, 
this testing pipeline is fundamentally unsound because the first step, AST, is 
performed on Mueller-Hinton Broth (MHB), a rich laboratory medium that fails to 
recapitulate most aspects of host environments. So, the fact that clinical breakpoints 
are based on a foundational assay performed in vitro raises questions as to how 
relevant they are to patient outcome. 
Supporting this notion, several reports suggest that the clinical predictive value 
of AST in the assignment of appropriate therapy is limited. (1) Clinical observations 
have given rise to the “90–60” rule: “susceptible” infections respond well to 
appropriate therapy in 90% of cases, whereas “resistant” infections respond well to 
these antibiotics in 60% of cases (Doern & Brecher, 2011; Rex & Pfaller, 2002). (2) 
Pneumococcal patients treated with antibiotics that failed standard tests (discordant 
therapy) had similar treatment outcomes as those that passed standard tests 
(concordant therapy) (Yu et al., 2003). (3) AST-recommended antibiotics failed to 
clear Salmonella enterica Typhimurium and Enterobacter cloacae in murine models 
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of sepsis (Band et al., 2016; Kubicek-Sutherland et al., 2015). (4) An AST-
disqualified antibiotic cleared multidrug-resistant Gram-negative pathogens in 
murine pulmonary models of infection (Lin et al., 2015). Here we propose that the 
antimicrobial testing assay should be revamped to account for pathogen conditions 
in the host, and show several circumstances in which susceptibility testing in host-
mimicking media is more accurate than standard AST in predicting antibiotic 
efficacy in vivo. We have termed this behavior in vivo altered susceptibility (IVAS), 
providing insight into why some patients fail to respond to certain antibiotics despite 
passing standard tests for clinical use. 
2.2 Results 
2.2.1 Antibiotic MICs Are Markedly Different When Derived From Host-mimicking 
Media vs. Standard MHB Medium 
A collection of human and veterinary clinical isolates was subjected to 
antimicrobial susceptibility testing in host-mimicking media vs. standard MHB 
medium. Four host-mimicking media were examined including (i) Dulbecco's 
Modified Eagle Medium (DMEM), a tissue culture medium supporting mammalian 
cell growth (Dulbecco & Freeman, 1959); (ii) Lacks medium, supporting 
pneumococcal growth (Lacks, 1966; Trombe, Clavé, & Manias, 1992); (iii) modified 
Lacks medium (MLM), simulating the nasopharynx for invasive pneumococcal 
carriage (Hathaway et al., 2012); and (iv) low-phosphate, low-magnesium medium 
(LPM pH 5.5), simulating the macrophage phagosome in which many intracellular 
pathogens reside/replicate (Coombes, Brown, Valdez, Brumell, & Finlay, 2004; 
Steele-Mortimer, 2008). Emphasis was placed on the identification of pathogen-
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antibiotic combinations that exhibited altered MICs from host-mimicking media 
relative to standard MHB medium; and whose MICs crossed clinical breakpoint 
designations that are used to define isolates as susceptible (“S”), intermediate (“I”), 
or resistant (“R”), and can impact clinical decision making on appropriate antibiotic 
therapy. Thus, we sought to identify antibiotics for which a given pathogen is 
classified as “S” in MHB medium but “R” in host-mimicking media (S to R); and 
antibiotics for which a given pathogen is classified as “R” in MHB medium but “S” in 
host-mimicking media (R to S). 
Staphylococcus (MRSA; MSSA; CoNS) 
A panel of antibiotics used in human and veterinary medicine was tested for 
efficacy against clinical isolates of methicillin-resistant and -sensitive S. aureus 
(MRSA/MSSA), and coagulase negative Staphylococcus (CoNS) (Fig. 1). Growth of 
Staphylococcus in tissue culture medium and modified Lacks medium conferred 
increased susceptibility to azithromycin, erythromycin, and streptomycin relative to 
MHB medium (4 to 256-fold; Fig. 1a). Conversely, Staphylococcus exhibited 
increased resistance to daptomycin and rifampin in modified Lacks medium, and to 
tetracycline in tissue culture medium, relative to MHB medium (4 to 16-fold). Table 
1 lists pathogen-antibiotic combinations that exhibited at least an 8-fold change in 
MIC when derived in host-mimicking media vs. standard MHB medium and whose 
altered MICs crossed clinical breakpoint designations that advise on patient 
therapy. For example, antibiotics for which MRSA was classified as “R” in MHB 
medium, but classified as “S” in tissue culture medium (cephalothin); and antibiotics 
for which MSSA was classified as “I” in MHB medium, but classified as “S” in tissue 
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culture medium (erythromycin) (Table 2a). Notably, although many pathogen-
antibiotic combinations have significant changes in MIC in host-mimicking media, 
many do not cross breakpoint designations (R to S; S to R) and would not alter 
physician making on appropriate therapy. For example, 3/3 MRSA isolates exhibited 
a 4- to 32-fold increased susceptibility to oxacillin in tissue culture medium, but the 
“altered MICs” of two MRSA isolates did not cross clinical breakpoints. Thus, they 
remain “Resistant” to oxacillin as defined by AST standards for clinical use. 
S. pneumoniae 
Altered MICs were also examined for S. pneumoniae clinical isolates tested in 
host-mimicking media vs. standard MHB medium. Most S. pneumoniae strains 
tested showed increased susceptibility to azithromycin in tissue culture medium and 
modified Lacks medium relative to MHB medium; and increased resistance to 
daptomycin and trimethoprim in modified Lacks medium (4 to 32-fold; Fig. 1b). 
Many S. pneumoniae MICs derived in host-mimicking media crossed clinical 
breakpoint designations (listed in Table 1); e.g., antibiotics for which S. pneumoniae 
was classified as “S” in MHB medium, but classified as “R” in modified Lacks 
medium (trimethoprim); and those for which S. pneumoniae classified was “R” in 
MHB medium, but classified as “S” in modified Lacks medium (azithromycin) (Table 
2b). 
Gram-negative Bacteria 
Antibiotic efficacy was also examined for Gram-negative bacterial isolates tested 
in host-mimicking media vs. standard MHB medium. A subset of these antibiotics 
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(10 of 20), which were not subject to acute pH and/or media composition effects 
under LPM pH 5.5 conditions (Kubicek-Sutherland et al., 2015), were also 
interrogated. Several Gram-negative bacteria were associated with increased 
resistance to colistin or polymyxin B in tissue culture medium and LPM pH 5.5 
conditions relative to MHB medium (4 to 512-fold) (Fig. 1c). Growth of Yersinia spp. 
(4 of 4 isolates) was associated with increased susceptibility to trimethoprim and co-
trimoxazole in tissue culture medium relative to MHB medium (8 to 64-fold). Many 
Gram-negative bacteria MICs derived in host-mimicking media crossed clinical 
breakpoint designations (listed in Table 1); e.g., Salmonella Typhimurium (ST) 
susceptibility to colistin was classified as “S” in MHB medium but “R” in tissue 
culture medium (Table 2c–f). 
Comparison Summary of MICs Derived From Host-mimicking Media vs. 
Standard MHB Medium 
We evaluated the percentage of pathogen-antibiotic combinations that resulted 
in altered MICs when derived from host-mimicking media vs. standard MHB 
medium (Fig. 2a). Although the MICs obtained from host-mimicking media were 
comparable to those from MHB medium for approximately two-thirds of cases 
tested (852/1311), one third of these cases exhibited at least a 4-fold change in 
MIC, which may signal altered antibiotic susceptibility in vivo. Further, 8.2% 
(107/1311) of altered MICs derived from the host-mimicking media tested resulted 
in a change in clinical breakpoint designation, which may impact physician decision 
making (Fig. 2b). Taken together, these data suggest that inclusion of 
environmental factors normally present during host-pathogen interactions may 
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improve the predictive value of standard AST in identifying effective antibiotics to 
treat microbial infections. 
2.2.2 Drug Testing in Host-mimicking Media Improves the Assignment of 
Appropriate Antibiotic Therapy 
Several pathogen-antibiotic combinations that exhibited altered MICs in host-
mimicking media were tested for efficacy in murine models of sepsis. We focused 
on antibiotics whose MICs exhibited at least an 8-fold altered susceptibility in host-
mimicking media relative to standard MHB medium, and whose MICs crossed 
clinical breakpoint designations. This analysis was limited to human and veterinary 
clinical isolates that also infect mice. 
MRSA, MSSA 
All mice (10/10) survived infection with MRSA (USA300) following treatment with 
cephalothin or ceftriaxone (Fig. 3a ; P < 0.001), identified as efficacious in tissue 
culture medium even though these agents failed standard testing in MHB medium 
(R to S; R to I; Table 2a). Similarly, nearly all mice (8/10) survived MSSA (MT3307) 
infection following treatment with erythromycin (P < 0.001), identified as bioactive in 
tissue culture medium but relatively ineffective by standard testing (I to S). 
Treatment with co-trimoxazole, often used clinically (Holland et al., 2014), failed to 
improve survivorship (1/10; P = 1.0), as predicted by testing in tissue culture 
medium but not MHB medium (S to R). 
Further analysis was done using a MRSA isolate (MT3302) linked to a fatal case 
of human sepsis. AST in host-mimicking media was evaluated in an effort to 
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retroactively identify alternative therapeutic options. Treatment with cephalosporins 
(ceftriaxone or ceftiofur) resulted in high efficacy in murine models of MRSA sepsis 
(8/10; 7/10; P < 0.001; P < 0.01). Both of these antibiotics were identified as 
efficacious in tissue culture medium even though they were rejected by standard 
testing (R to I). Further, all mice (10/10) survived treatment with daptomycin and 
ciprofloxacin (Fig. 3a; P < 0.001), as predicted by testing of daptomycin in standard 
MHB medium and tissue culture medium; and of ciprofloxacin in all media examined 
(Table 2a). Notably, testing of daptomycin in modified Lacks medium predicted 
resistance (S to R), indicating that this drug may be effective against certain types 
of infections but not others (e.g., systemic vs. localized). 
S. pneumoniae 
Despite passing standard testing in MHB medium, trimethoprim failed to protect 
mice (0/10) from SPN infection (strain Daw 25) (Fig. 3b; P = 1.0), as predicted by 
testing in modified Lacks medium (S to R; Table 2b). Further, all mice (10/10) 
survived following treatment with ceftriaxone (P < 0.001), for which susceptibility 
was indicated in all media tested. 
Gram-negative Bacteria 
Colistin, a drug of last resort (Yahav, Farbman, Leibovici, & Paul, 2012), failed to 
protect mice (1/10) from infection with S. Typhimurium (ST14028) (Fig. 3c; P = 1.0), 
as predicted by testing in tissue culture medium (S to R; Table 2c). Conversely, all 
mice (10/10) survived treatment with ciprofloxacin (P < 0.001), for which 
susceptibility was indicated in all media tested. Additionally, most mice (8/10) 
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survived infection with K. pneumoniae following treatment with tetracycline (P < 
0.001). Such efficacy was predicted by standard testing in MHB and LPM pH 5.5 
media (S to S), which mimics the macrophage phagosome wherein K. pneumoniae 
resides and replicates during infection (Cano et al., 2015) (Table 2f). Such efficacy 
was comparable to treatment with ciprofloxacin (8/10; P < 0.001) that has 
established activity against intracellular pathogens (Carryn et al., 2003). Notably, 
testing of tetracycline in tissue culture medium predicted resistance (S to R), 
suggesting that testing in media that reflect the intracellular lifestyle of K. 
pneumoniae is a more accurate predictor of treatment outcome for this pathogen. 
Bacterial Clearance 
Bacterial clearance from circulation in the blood was investigated following 
treatment with antibiotics predicted as highly efficacious by testing in standard MHB 
medium (co-trimoxazole) or tissue culture medium (azithromycin), respectively 
(Table 2a). Treatment with the AST-recommended antibiotic, co-trimoxazole, was 
ineffective in MSSA (MT3307) clearance as predicted by testing in host-mimicking 
media (S to R) (Fig. 3d). This treated cohort exhibited a progressive bacteremia (up 
to 2.5 × 105 colony forming units (CFU)/ml blood by day 6), with all mice (10/10) 
succumbing to infection by day 10 (open boxes). Such efficacy was comparable to 
that of untreated animals (open circles). Conversely, as predicted by testing in 
tissue culture medium, azithromycin was able to clear MSSA from circulation, with 
all mice (10/10) surviving the infection and harboring ≤ 2 × 103 CFU/ml in the blood 
at day 10 (closed boxes; P < 0.001). These data suggest that drug testing in host-
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mimicking media improves the predictive value of standard AST in the assignment 
of appropriate therapy. 
2.2.3 Addition of NaHCO3 to Standard MHB Medium Improves the Accuracy of 
Antibiotic Efficacy In Vivo 
We suspected that sodium bicarbonate (NaHCO3) may be a key in vivo 
molecule contributing to antibiotic susceptibility for a number of pathogens for the 
following reasons. NaHCO3 serves as an abundant ionic factor present in 
mammalian tissues that stimulates global changes in bacterial structure, gene 
expression, and membrane permeability that correspond to increased susceptibility 
to human cationic antimicrobial peptides (Dorschner et al., 2006). NaHCO3 is 
present in nearly all host-mimicking media examined that resulted in altered 
antibiotic susceptibility relative to MHB medium. Thus, we evaluated whether 
supplementation of standard MHB medium with physiological levels of NaHCO3 
improved the predictive value of the AST standard for clinical use. This analysis was 
initially focused on Staphylococcus-antibiotic combinations that exhibited at least an 
8-fold change in MIC in tissue culture medium vs. MHB medium, representing 
13.5% (31/230) of combinations examined (Fig. 1a, top panel). 
We investigated the fold-change between MICs derived in MHB medium in the 
presence/absence of NaHCO3 (test/standard condition; left of slash); and in tissue 
culture medium in the absence/presence of NaHCO3 (test/standard condition; right 
of slash) (Fig. 4a ; Table 3a). Increased susceptibility is depicted in blue; increased 
resistance is depicted in red. Four phenotypic classes were identified. 
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Class 1 (21/31). Addition of NaHCO3 to MHB medium resulted in MICs similar to 
tissue culture medium; its removal from tissue culture medium resulted in MICs 
similar to MHB medium (azithromycin, erythromycin, tetracycline). 
Class 2 (5/31). Addition of NaHCO3 to MHB medium resulted in MICs similar to 
tissue culture medium; its removal from tissue culture medium had no effect on the 
MIC (ceftriaxone, ceftiofur). 
Class 3 (2/31). Addition of NaHCO3 addition to MHB medium had no MIC effect; 
its removal from tissue culture medium resulted in MICs similar to MHB medium 
(oxacillin). 
Class 4 (3/31). Addition/removal of NaHCO3 had no effect on MICs in MHB 
medium or tissue culture medium (trimethoprim). These data indicate that addition 
of NaHCO3 to MHB medium restored the altered susceptibility observed in tissue 
culture medium in 83.9% (26 of 31) of cases tested. 
 
Next, we examined whether physiological levels of NaHCO3 in MHB medium 
were required to stimulate the altered susceptibility observed in tissue culture 
medium. A dose response analysis of MRSA (USA300; MT3302) and MSSA 
(MT3307) strains revealed that physiological levels of NaHCO3 (~25 mM) (Mayo 
Clinic, 2017) were necessary to induce altered antibiotic susceptibility in MHB 
medium (Fig. 4b). These data suggest that NaHCO3 may be a key in vivo 
component contributing to antibiotic susceptibility for a number of pathogens. 
Supporting this suggestion, supplementation of MHB medium with physiological 
levels of NaHCO3 also resulted in altered drug susceptibilities in S. pneumoniae and 
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Salmonella spp. isolates (Fig. 4c; Table 3b, c). Further, many altered MICs crossed 
clinical breakpoint designations (listed in Table 1), and such predicted changes in 
antibiotic efficacy were confirmed in mouse models of infection and sepsis (Fig. 2a); 
e.g., MRSA (cephalothin [R to S]; ceftriaxone [R to I]); and MSSA (erythromycin [I to 
S]); (Table 3a). These findings suggest that supplementation of standard MHB 
medium with physiological levels of NaHCO3 improved the predictive value of AST 
in the assignment of appropriate antibiotics for therapeutic intervention. 
2.3 Discussion 
Multidrug-resistant bacteria are a significant cause of sepsis, the most common 
cause of death in hospitalized patients, with an annual incidence of 1 million cases 
and 200,000 deaths in the U.S. alone (Deutschman & Tracey, 2014). This dire 
perspective reflects the failed efforts to fully contain bacteria with the misuse of 
antibiotics, and the legal, financial, and scientific hurdles to discovering new ones. 
We demonstrate that one viable approach to address this alarming threat is to 
incorporate host-mimicking media in standard AST methods for clinical use. 
Validation of the improved predictive value of AST in the assignment of appropriate 
antibiotic therapy was provided in several Gram-positive and -negative animal 
models of infection and sepsis. Our findings suggest that standard AST may be 
hindering optimal patient treatment, and slowing the process of discovery of new, 
effective, and safe antibiotics because it disqualifies efficacious compounds. 
Susceptibility testing that accounts for the biology of a pathogen in the context of its 
host may enable the re-purposing of omitted antibiotics while aiding the discovery of 
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new ones by screening compounds under conditions that more accurately reflect 
the host milieu. 
Altered drug susceptibility in vivo provides insight as to why some patients fail to 
respond to certain antibiotics despite passing standard susceptibility tests. Our 
findings with a MRSA isolate from a deceased patient provide a clear example as 
antibiotics omitted by standard AST were highly efficacious in bacterial clearance. If 
these alternative therapeutic options had been made available to clinicians 
managing this case, it may have changed the patient outcome. Additionally, we 
show that supplementation of standard MHB medium with physiological levels of 
sodium bicarbonate improved the predictive value of AST in the assignment of 
appropriate therapy. The molecular basis likely involves the role of NaHCO3 as an 
abundant ionic factor that stimulates global changes in bacterial structure and gene 
expression, leading to alterations in bacterial cell wall thickness and membrane 
permeability that correspond with increased susceptibility to human cationic 
antimicrobial peptides (Dorschner et al., 2006). Two potential alternative 
mechanisms include the role of bicarbonate in the maintenance of blood pH 
(Hermansen & Osnes, 1972; Rosenthal, 1948); and/or the inhibition of growth and 
viability of periodontal pathogens (Newbrun, Hoover, & Ryder, 1984). However, 
these mechanisms are unlikely to play a role in the improved predictive value of 
AST due to the inclusion of Tris buffer in the test media to preclude bicarbonate-
mediated pH fluctuations that can affect antibiotic potency and bacterial cell viability. 
Standard AST in clinical use has likely contributed to the alarming rise of 
multidrug-resistant bacteria in hospitals because high doses of ineffective antibiotics 
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are given to infected patients without the knowledge that the host environment may 
render bacteria inherently resistant to the antibiotics prescribed to kill them. Based 
on the findings of this study, rather than extending the dose/duration of an antibiotic 
that is not effective, physicians might consider that the more appropriate approach 
is to prescribe a totally different antibiotic. Standard AST in combination with host-
mimicking media may serve as a valuable tool in advising clinicians on appropriate 
antibiotic therapy. Antibiotics identified by both approaches were efficacious in 
every animal model examined; thus, such cases should bestow high confidence in 
clinical decision making on appropriate therapy. Conversely, physicians should 
exercise caution in cases where marked MIC disparities occur between testing in 
host-mimicking media vs. standard MHB medium. Further, predicted drug failure in 
a particular host-mimicking media may indicate that certain drugs may be effective 
against certain types of infections but not others (e.g., systemic vs. localized). 
Supporting this suggestion, MRSA inactivates daptomycin by releasing membrane 
phospholipids under certain experimental conditions (Pader et al., 2016); and herein 
we show that a MRSA isolate was susceptible to daptomycin in tissue culture 
medium and in a murine model of sepsis, but displayed resistance in other host-
mimicking media examined (minimal Lacks medium). 
Future considerations must be given to host-pathogen interactions that can also 
influence drug susceptibility. (1) Animals, including primates, often tolerate drugs 
differently than humans (pharmacokinetic parameters such as drug clearance, 
volume of distribution, and half-life can result in unanticipated changes in 
antimicrobial efficacy) (Ambrose et al., 2007; Deziel et al., 2005). (2) Bacterial 
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community composition can compromise antibiotic efficacy (antibiotic deactivation 
or biofilm production provides passive resistance for all microbes within a 
polymicrobial environment) (Sorg et al., 2016; Vega & Gore, 2014). (3) Antimicrobial 
selection is based on drug concentrations achieved in plasma, but concentrations 
achieved in different tissues and sites of infection may be greater or less depending 
on the drug's properties (pH at the infection site or within an organelle can dictate 
lipid solubility of the drug or its distribution in cells and tissues) (Logan, Funk, Axcell, 
& Krise, 2012). (4) Antibiotic resistance may be inadvertently triggered by diet, 
underlying conditions in the patient, or by clinical interventions that may disrupt drug 
efficacy (ascorbic acid treatment of urinary tract infections to lower urine pH) 
(Carlsson, Wiklund, Engstrand, Weitzberg, & Lundberg, 2001). (5) Many patients 
that develop multidrug-resistant infections have co-morbidities, immunosuppressive 
therapy and/or the presence of invasive medical devices that impact susceptibility to 
indicated pathogens (Paterson & Bonomo, 2005). 
Our findings suggest that the susceptibility testing in media that reflect the host 
milieu will not only improve the predictive value of AST in the assignment of 
appropriate antibiotic therapy, but also provides a new paradigm for drug discovery 
and therapeutic intervention for infectious diseases. However, such testing will 
always be open to further improvement, especially as we learn more about the 
subtle nuances of host-pathogen interactions in natural environments that influence 
the impact of antibiotics on bacterial clearance (e.g., virulence factors, ecological 
factors, and cell physiological parameters). 
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Figures 
 
Figure 1.  Comparison of pathogen-antibiotic combinations that exhibited 
altered MICs derived from host-mimicking media relative to standard MHB 
medium. A panel of antibiotics was screened for altered MICs against 
(a) Staphylococcus spp., (b) S. pneumoniae, and (c) Gram-negative bacteria when 
tested in Dulbecco's Modified Eagle Medium (DMEM), Lacks medium, modified 
Lacks medium (MLM), low-phosphate, low-magnesium medium (LPM pH 5.5) 
relative to standard MHB medium, according to CLSI guidelines (Clinical and 
Laboratory Standards Institute, 2012a; Wiegand, Hilpert, & Hancock, 2008). Values 
depict the fold-change in MICs when derived in host-mimicking media relative to 
standard MHB medium (test/standard condition). Increased susceptibility depicted 
in blue; increased resistance depicted in red. MIC values were obtained from at 
least 6 independent determinations.
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Table 1. AST in host-mimicking media identifies MICs that cross clinical 
breakpoint designations which advise on patient therapy. 
 
Drug Target Pathogen 
Host-mimicking 
media 
Clinical 
breakpoint 
Increased susceptibility 
Cephalothin Cell wall MRSA1 
DMEM/MHB + 
NaHCO3 
R to S 
Ceftriaxone Cell wall MRSA1–3 
DMEM/MHB + 
NaHCO3 
R to S, I 
Oxacillin Cell wall MRSA3 DMEM R to S 
Ampicillin Cell wall CoNS
1; SPN1,2 MLM/DMEM R, I to S 
Trimethoprim Folate SPN
2 DMEM R to S 
Azithromycin Protein CoNS
1,3; SPN1,2 MLM/MHB + NaHCO3 R to S, I 
Erythromycin Protein MSSA1,2; CoNS1 
DMEM/MLM/MHB + 
NaHCO3 
R, I to I, S 
Streptomycin Protein MRSA1; MSSA1–4 DMEM/MLM R, I to S 
     
Decreased susceptibility 
Colistin Membrane ST; PA DMEM S to R 
Daptomycin Membrane 
MRSA2,3; 
MSSA1–4; 
CoNS1–3 
MLM S to R 
Ceftriaxone Cell wall SPN
3 DMEM S to R 
Ampicillin Cell wall SPN
3; CF 
DMEM/MHB + 
NaHCO3 
S, I to R, I 
Trimethoprim Folate MSSA
1; SPN4, 5 DMEM/MLM S to R 
Co-
Trimoxazole 
Folate MSSA
1; SPN4, 5 DMEM/MLM S to R, I 
Gentamicin Protein PA DMEM S to R 
Tetracycline Protein 
KPN; CF; ST; 
SC; EC1–3; YP1–4 
DMEM/MHB + 
NaHCO3 
S to R, I 
Enrofloxacin DNA EC
4 DMEM S to R 
 
Depicted are pathogen-antibiotic combinations that exhibited altered MICs derived 
from host-mimicking media relative to standard MHB medium; and whose MICs 
crossed clinical breakpoint designations that are used to define isolates as 
susceptible (“S”), intermediate (“I”), or resistant (“R”), and advise on patient therapy. 
R to S refers to an “R” classification when tested for susceptibility in MHB medium 
but an “S” classification in host-mimicking media. MRSA1–3 (USA 300; Blood; 
Wound); CoNS1–3 (S. epidermidis; S. lugdunensis; S. warneri); SPN1–5 (serotype 6; 
6; 23; 11; 35C); MSSA1–4 (Wound; Sputum; Urine; Blood); ST (S. Typhimurium); PA 
(P. aeruginosa); CF (C. freundii); KPN (K. pneumoniae); SC (S. Choleraesuis); EC1–
   
26 
 
4 (E. coli ATCC 25922; UPEC J96; UPEC ATCC 11775; EPEC χ2927); YP1–4 (YPIII; 
IP32953; IP2515; IP2666). Clinical breakpoint concentrations for listed drugs 
(Clinical and Laboratory Standards Institute, 2012b, 2013, 2014; European 
Committee on Antimicrobial Susceptibility Testing, 2016; Fuchs, Barry, & Brown, 
1997; Landman, Georgescu, Martin, & Quale, 2008; Societe Francaise de 
Microbiologie, 2012). 
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Table 2a. Antimicrobial susceptibility testing in host-mimicking media 
(Staphylococcus)  
 
 
"Susceptible" MIC
"Intermediate" MIC
"Resistant" MIC
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 1 0.5 4 2 32 4 32 4 64 8 32 8 512 16 128 32
MT3302 MRSA Blood 0.5 0.5 4 2 8 2 2 2 16 4 8 4 128 16 64 32
MT3315 MRSA Wound 0.5 0.25 4 2 8 0.5 1 0.5 16 4 8 4 64 8 64 16
MT3305 MSSA Blood 0.5 0.5 4 2 0.5 0.25 0.5 0.25 1 2 1 1 4 2 4 4
MT3307 MSSA Wound 0.5 0.5 8 2 0.125 0.0625 0.25 0.25 1 1 1 1 2 2 4 4
MT3309 MSSA Urine 0.5 1 4 2 0.25 0.125 0.5 0.25 1 1 1 1 4 2 4 2
MT3314 MSSA Sputum 1 0.5 8 2 0.25 0.125 0.25 0.25 1 1 1 0.5 2 2 4 4
MT3317 CoN S. lugdunensis 0.25 0.125 4 2 0.5 0.5 1 0.5 0.5 2 1 0.5 2 4 4 4
MT3320 CoN S. epidermidis 0.5 0.5 8 2 0.125 0.25 0.125 0.125 0.5 0.5 0.125 0.5 1 2 4 2
MT3321 CoN S. warneri 0.5 0.125 4 2 0.125 0.03125 0.125 0.0625 0.25 0.5 0.25 0.25 2 0.5 2 1
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 512 256 64 64 64 16 128 16 2 2 1 1 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
MT3302 MRSA Blood 256 128 64 256 64 4 32 8 2 4 0.5 1 0.125/2.4 0.125/2.4 0.0625/1.2 0.25/4.8
MT3315 MRSA Wound 8 0.5 1 1 32 1 64 4 2 4 0.5 1 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
MT3305 MSSA Blood 2 2 2 2 0.25 0.25 0.25 0.25 1 2 1 1 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
MT3307 MSSA Wound 0.125 0.125 0.03125 0.0625 0.25 0.125 0.125 0.125 2 >512 1 1 0.125/2.4 >64/1216 0.0625/1.2 0.25/4.8
MT3309 MSSA Urine 0.125 0.125 0.125 0.125 0.25 0.125 0.25 0.125 1 1 1 0.5 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
MT3314 MSSA Sputum 0.125 0.125 0.125 0.125 0.25 0.125 0.25 0.125 2 1 1 1 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
MT3317 CoN S. lugdunensis 128 64 8 16 0.5 0.5 0.5 0.25 16 16 8 8 0.25/4.8 0.5/9.5 0.25/4.8 0.5/9.5
MT3320 CoN S. epidermidis 8 16 0.25 1 0.125 0.25 0.25 0.25 1 1 0.5 0.5 0.25/4.8 0.125/2.4 0.125/2.4 0.25/4.8
MT3321 CoN S. warneri 0.03125 0.0156 0.0156 0.03125 0.125 0.125 0.0625 0.125 2 2 4 1 0.0625/1.2 0.125/2.4 0.25/4.8 0.125/2.4
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 128 64 32 64 16 4 2 8 > 512 > 512 > 512 > 512 1 2 0.5 1
MT3302 MRSA Blood 128 32 16 64 8 2 2 8 > 512 > 512 > 512 > 512 1 4 0.25 1
MT3315 MRSA Wound 128 64 16 64 4 1 1 8 > 512 > 512 512 > 512 128 >512 128 256
MT3305 MSSA Blood 128 64 32 64 16 2 2 8 8 16 4 8 1 2 0.25 1
MT3307 MSSA Wound 256 64 32 128 16 4 2 16 8 16 2 8 1 4 0.25 2
MT3309 MSSA Urine 128 64 32 64 32 4 2 8 4 8 4 8 0.5 2 0.25 1
MT3314 MSSA Sputum 256 64 64 128 32 2 4 16 4 8 4 8 1 2 0.5 1
MT3317 CoN S. lugdunensis 64 32 16 32 4 1 1 8 1 4 1 4 0.125 0.5 0.125 0.25
MT3320 CoN S. epidermidis 128 64 64 128 4 0.5 0.25 4 4 8 0.5 4 0.125 0.5 0.03125 0.25
MT3321 CoN S. warneri 64 32 16 32 4 1 2 8 1 4 2 8 0.125 0.5 0.125 0.5
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 4 4 2 2 0.5 4 1 1 128 8 16 32 64 8 16 16
MT3302 MRSA Blood 2 2 1 2 0.5 2 0.25 1 128 8 8 32 128 8 8 16
MT3315 MRSA Wound 2 2 1 2 0.25 1 0.25 1 1 0.125 0.0625 0.125 0.25 0.0625 0.0625 0.125
MT3305 MSSA Blood 2 2 2 2 0.5 0.5 0.5 1 >512 >512 >512 >512 >512 >512 >512 >512
MT3307 MSSA Wound 2 2 1 2 0.5 4 0.5 1 2 0.125 0.125 0.25 1 0.125 0.0625 0.125
MT3309 MSSA Urine 2 2 1 2 4 8 4 4 1 0.125 0.125 0.25 0.5 0.125 0.125 0.125
MT3314 MSSA Sputum 2 2 1 2 0.5 2 1 1 2 0.125 0.125 0.25 1 0.125 0.125 0.25
MT3317 CoN S. lugdunensis 1 1 0.5 1 0.25 1 0.25 0.5 0.25 0.0625 0.0625 0.125 0.125 0.03125 0.0625 0.0625
MT3320 CoN S. epidermidis 2 2 1 1 0.5 4 0.5 1 256 32 1 32 128 32 2 32
MT3321 CoN S. warneri 2 2 1 2 0.5 4 2 1 256 32 16 64 256 32 32 64
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 16 8 8 8 4 4 4 4 0.125 0.0625 0.0625 0.125 0.0078 0.0156 0.0625 0.0078
MT3302 MRSA Blood 8 4 4 8 4 4 4 4 0.25 0.125 0.0625 0.125 0.0078 0.0156 0.0625 0.0156
MT3315 MRSA Wound 8 8 4 4 4 4 4 4 0.125 0.125 0.0625 0.125 0.0078 0.03125 0.0625 0.0156
MT3305 MSSA Blood 16 8 8 8 4 4 4 4 0.25 0.125 0.125 0.125 0.0156 0.0156 0.125 0.0156
MT3307 MSSA Wound 16 16 8 8 4 4 4 4 0.25 0.0625 0.0625 0.125 0.0078 0.0156 0.125 0.0156
MT3309 MSSA Urine 8 4 8 8 8 4 4 4 0.25 0.125 0.0625 0.125 0.0078 0.0156 0.125 0.0156
MT3314 MSSA Sputum 8 4 8 8 4 4 4 4 0.25 0.125 0.125 0.125 0.0156 0.0156 0.25 0.0156
MT3317 CoN S. lugdunensis 8 8 4 4 2 4 2 2 0.125 0.03125 0.0625 0.0625 0.0078 0.0156 0.03125 0.0078
MT3320 CoN S. epidermidis 8 8 2 4 4 8 2 4 0.125 0.125 0.03125 0.125 0.0078 0.03125 0.0625 0.0156
MT3321 CoN S. warneri 8 8 8 8 4 4 4 4 0.125 0.0625 0.0625 0.0625 0.002 0.0078 0.0156 0.0078
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 64 256 512 64 0.5 0.5 1 1 0.125 0.25 0.5 0.25
MT3302 MRSA Blood 64 256 512 256 0.25 0.25 0.5 0.5 0.25 0.25 0.5 0.25
MT3315 MRSA Wound 256 >512 >512 >512 8 16 32 32 4 4 8 8
MT3305 MSSA Blood 64 128 512 128 0.125 0.25 0.25 0.25 0.0625 0.25 0.25 0.25
MT3307 MSSA Wound 32 256 512 128 0.25 0.5 0.5 0.5 0.125 0.25 0.25 0.125
MT3309 MSSA Urine 256 >512 >512 >512 16 16 32 16 4 8 16 4
MT3314 MSSA Sputum 32 128 256 64 0.25 0.25 0.5 0.5 0.125 0.25 0.25 0.125
MT3317 CoN S. lugdunensis 64 512 256 128 0.25 0.25 0.25 0.125 0.125 0.25 0.25 0.125
MT3320 CoN S. epidermidis 32 256 256 64 0.125 0.25 0.25 0.25 0.125 0.25 0.125 0.25
MT3321 CoN S. warneri 256 512 512 128 0.25 0.5 0.25 0.25 0.25 0.5 0.25 0.125
aAll Clinical Breakpoints are referenced from the CLSI 2014 twenty-fourth informational supplement 30 unless otherwise indicated
MHB, DMEM, MLM and Lacks Medium MICs were determined by broth microdilution in accordance with CLSI guidelines. DMEM MICs were incubated in a 5% CO 2 incubator. S = 
Susceptible, NS = Non-Susceptible, I = Intermediate, R = Resistant
Clinical Breakpoints:
Clinical Breakpoints:
Clinical Breakpoints:
Nalidixic Acid MIC (µg/mL) Ciprofloxacin MIC (µg/mL)
S ≤ 1; I = 2; R ≥ 4
Enrofloxacin MIC (µg/mL)
S ≤ 8; I = 16; R ≥ 32
S ≤ 4; R ≥ 8
Rifampin MIC (µg/mL)
S ≤ 1; I = 2; R ≥ 4
S ≤ 4; I = 8; R ≥ 16 S ≤ 2; I = 4; R ≥ 8 S ≤ 0.5; I = 1 - 4; R ≥ 8 
S ≤ 0.5; I = 1 - 2; R ≥ 4 
Table 3.1a. Antimicrobial susceptibility testing in host-mimicking media (Staphylococcus)
Spectinomycin MIC (µg/mL)
Clinical Breakpointsa:
Chloramphenicol MIC (µg/mL)
Clinical Breakpointsa:
S ≤ 16; I = 32; R ≥ 64
Clindamycin MIC (µg/mL)
Cephalothin MIC (µg/mL) Ceftiofur MIC (µg/mL)
S ≤ 2; I = 4; R ≥ 8164
S ≤  8; I = 16; R ≥ 32165
Clinical Breakpoints: S ≤ 0.25; R ≥ 0.5
Streptomycin MIC (µg/mL) Kanamycin MIC (µg/mL)
Florfenicol MIC (µg/mL)
Clinical Breakpoints:
Ceftriaxone MIC (µg/mL)
S ≤ 8; I =16-32; R ≥ 64163S ≤ 8; I = 16; R ≥ 32163
S ≤ 0.25; R ≥ 0.5163
Daptomycin MIC (µg/mL)
S ≤ 1; NS ≥ 2
S ≤ 8; R ≥ 16
Ampicillin MIC (µg/mL) Trimethoprim MIC (µg/mL) Co-Trimoxazole MIC (µg/mL)Oxacillin MIC (µg/mL)
S ≤ 2/38; R ≥ 4/76
Gentamicin MIC (µg/mL)
Erythromycin MIC (µg/mL)
S ≤ 2; R ≥ 4
Tetracycline MIC (µg/mL) Azithromycin MIC (µg/mL)Linezolid MIC (µg/mL)
S ≤ 4; I = 8; R ≥ 16 
"Susceptible" MIC
"Intermediate" MIC
"Resistant" MIC
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 1 0.5 4 2 32 4 32 4 64 8 32 8 512 16 128 32
MT3302 MRSA Blood 0.5 0.5 4 2 8 2 2 2 16 4 8 4 128 16 64 32
MT3315 MRSA Wound 0.5 0.25 4 2 8 0.5 1 0.5 16 4 8 4 64 8 64 16
MT3305 MSSA Blood 0.5 0.5 4 2 0.5 0.25 0.5 0.25 1 2 1 1 4 2 4 4
MT3307 MSSA Wound 0.5 0.5 8 2 0.125 0.0625 0.25 0.25 1 1 1 1 2 2 4 4
MT3309 MSSA Urine 0.5 1 4 2 0.25 0.125 0.5 0.25 1 1 1 1 4 2 4 2
MT3314 MSSA Sputum 1 0.5 8 2 0.25 0.125 0.25 0.25 1 1 1 0.5 2 2 4 4
MT3317 CoN S. lugdunensis 0.25 0.125 4 2 0.5 0.5 1 0.5 0.5 2 1 0.5 2 4 4 4
320 CoN S. epidermidis 0.5 0.5 8 2 0.125 0.25 0.125 0.125 0.5 0.5 0.125 0.5 1 2 4 2
321 CoN . warneri 0.5 0.125 4 2 0.125 0.03125 0.125 0.0625 0.25 0.5 0.25 0.25 2 0.5 2 1
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 512 256 64 64 64 16 128 16 2 2 1 1 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
MT3302 MRSA Blood 256 128 64 256 64 4 32 8 2 4 0.5 1 0.125/2.4 0.125/2.4 0.0625/1.2 0.25/4.8
MT3315 MRSA Wound 8 0.5 1 1 32 1 64 4 2 4 0.5 1 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
MT3305 MSSA Blood 2 2 2 2 0.25 0.25 0.25 0.25 1 2 1 1 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
MT3307 MSSA Wound 0.125 0.125 0.03125 0.0625 0.25 0.125 0.125 0.125 2 >512 1 1 0.125/2.4 >64/1216 0.0625/1.2 0.25/4.8
MT3309 MSSA Urine 0.125 0.125 0.125 0.125 0.25 0.125 0.25 0.125 1 1 1 0.5 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
3314 MSSA Sputum 0.125 0.125 0.125 0.125 0.25 0.125 0.25 0.125 2 1 1 1 0.0625/1.2 0.125/2.4 0.0625/1.2 0.125/2.4
317 CoN S. lugdunensis 128 64 8 16 0.5 0.5 0.5 0.25 16 6 8 8 0.25/4.8 0.5/9.5 0.25/4.8 0.5/9.5
320 CoN S. epidermidis 8 16 0.25 1 0.125 0.25 0.25 0.25 1 1 0.5 0.5 0.25/4.8 0.125/2.4 0.125/2.4 0.25/4.8
T3321 CoN S. warneri 0.03125 0.0156 0.0156 0.03125 0.125 0.125 0.0625 0.125 2 2 4 1 0.0625/1.2 0.125/2.4 0.25/4.8 0.125/2.4
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 128 64 32 64 16 4 2 8 > 512 > 512 > 512 > 512 1 2 0.5 1
MT3302 MRSA Blood 128 32 16 64 8 2 2 8 > 512 > 512 > 512 > 512 1 4 0.25 1
MT3315 MRSA Wound 128 64 16 64 4 1 1 8 > 512 > 512 512 > 512 128 >512 128 256
MT3305 MSSA Blood 128 64 32 64 16 2 2 8 8 16 4 8 1 2 0.25 1
MT3307 M SA Wound 256 64 32 128 16 4 2 16 8 16 2 8 1 4 0.2 2
309 S rine 128 64 32 64 32 4 2 8 4 8 4 8 0. 2 0.25 1
314 MSSA Sputum 256 64 64 128 32 2 4 16 4 8 4 8 1 2 0.5 1
T3317 CoN S. lugdunensis 64 32 16 32 4 1 1 8 1 4 1 4 0.125 0.5 0.125 0.25
MT3320 CoN S. epidermidis 128 64 64 128 4 0.5 0.25 4 4 8 0.5 4 0.125 0.5 0.03125 0.25
MT3321 CoN S. warneri 64 32 16 32 4 1 2 8 1 4 2 8 0.125 0.5 0.125 0.5
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
MT3322 MRSA USA300 4 4 2 2 0.5 4 1 1 128 8 16 32 64 8 16 16
MT3302 MRSA Blood 2 2 1 2 0.5 2 0.25 1 128 8 8 32 128 8 8 16
MT3315 MRSA Wound 2 2 1 2 0.25 1 0.25 1 1 0.125 0.0625 0.125 0.25 0.0625 0.0625 0.125
MT3305 MSSA Blood 2 2 2 2 0.5 0.5 0.5 1 >512 >512 >51 >512 >512 >512 >512 >512
MT3307 MSSA Wound 2 2 1 2 0.5 4 0.5 1 2 0.125 0.125 0.25 1 0.125 0.0625 0.125
MT3309 MSSA Urine 2 2 1 2 4 8 4 4 1 0.125 0.125 0.25 0.5 0.125 0.125 0.125
MT3314 MSSA Sputum 2 2 1 2 0.5 2 1 1 2 0.125 0.125 0.25 1 0.125 0.125 0.25
MT3317 CoN S. lugdunensis 1 1 0.5 1 0.25 1 0.25 0.5 0.25 0.0625 0.0625 0.125 0.125 0.03125 0.0625 0.0625
MT3320 CoN S. epidermidis 2 2 1 1 0.5 4 0.5 1 256 32 1 32 128 32 2 32
MT3321 CoN S. warneri 2 2 1 2 0.5 4 2 1 256 32 16 64 256 32 32 64
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
322 MRSA USA300 16 8 8 8 4 4 4 4 0.125 0.0 25 0.0625 0.125 0.0078 0.0156 0.0625 0.0078
302 MRSA Blood 8 4 4 8 4 4 4 4 0.25 0.125 0.0625 0.125 0.0078 0.0156 0.0625 0.0156
MT3315 MRSA Wound 8 8 4 4 4 4 4 4 0.125 0.125 0.0625 0.125 0.0078 0.03125 0.0625 0.0156
MT3305 MSSA Blood 16 8 8 8 4 4 4 4 0.25 0.125 0.125 0.125 0.0156 0.0156 0.125 0.0156
MT3307 MSSA Wound 16 16 8 8 4 4 4 4 0.25 0.0625 0.0625 0.125 0.0078 0.0156 0.125 0.0156
MT3309 MSSA Urine 8 4 8 8 8 4 4 4 0.25 0.125 0.0625 0.125 0.0078 0.0156 0.125 0.0156
MT3314 MSSA Sputum 8 4 8 8 4 4 4 4 0.25 0.125 0.125 0.125 0.0156 0.0156 0.25 0.0156
MT3317 CoN S. lugdunensis 8 8 4 4 2 4 2 2 0.125 0.03125 0.0625 0.0625 0.0078 0.0156 0.03125 0.0078
MT3320 CoN S. epidermidis 8 8 2 4 4 8 2 4 0.125 0.125 0.03125 0.125 0.0078 0.03125 0.0625 0.0156
MT3321 CoN S. warneri 8 8 8 8 4 4 4 4 0.125 0.0625 0.0625 0.0625 0.002 0.0078 0.0156 0.0078
Strain # Strain Name Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium Ca-MHB
DMEM + 
5% LB MLM
Lacks 
Medium
322 MRSA USA300 64 256 512 64 0.5 0.5 1 1 0.125 0. .5 25
302 MR A Blood 64 256 512 256 0.25 0.25 0.5 0.5 0.25 0. 0.5 0.25
T3315 MRSA Wound 256 >512 >512 >512 8 16 32 32 4 4 8 8
MT3305 MSSA Blood 64 128 512 128 0.125 0.25 0.25 0.25 0.0625 0.25 0.25 0.25
MT3307 MSSA Wound 32 256 512 128 0.25 0.5 0.5 0.5 0.125 0.25 0.25 0.125
MT3309 MSSA Urine 256 >512 >512 >512 16 16 32 16 4 8 16 4
MT3314 MSSA Sputum 32 128 256 64 0.25 0.25 0.5 0.5 0.125 0.25 0.25 0.125
MT3317 CoN S. lugdunensis 64 512 256 128 0.25 0.25 0.25 0.125 0.125 0.25 0.25 0.125
MT3320 CoN S. epidermidis 32 256 256 64 0.125 0.25 0.25 0.25 0.125 0.25 0.125 0.25
MT3321 CoN S. warneri 256 512 512 128 0.25 0.5 0.25 0.25 0.25 0.5 0.25 0.125
aAll Clinical Breakpoints are referenced from the CLSI 2014 twenty-fourth informational supplement 30 unless otherwise indicated
MHB, DMEM, MLM and Lacks Medium MICs were determined by broth microdilution in accordance with CLSI guidelines. DMEM MICs were incubated in a 5% CO 2 incubator. S = 
Susceptible, NS = Non-Susceptible, I = Intermediate, R = Resistant
Clinical Breakpoints:
Clinical Breakpoints:
Clinical Breakpoints:
Nalidixic Acid MIC (µg/mL) Ciprofloxacin MIC (µg/mL)
S ≤ 1; I = 2; R ≥ 4
Enrofloxacin MIC (µg/mL)
S ≤ 8; I = 16; R ≥ 32
S ≤ 4; R ≥ 8
Rifampin MIC (µg/mL)
S ≤ 1; I = 2; R ≥ 4
S ≤ 4; I = 8; R ≥ 16 S ≤ 2; I = 4; R ≥ 8 S ≤ 0.5; I = 1 - 4; R ≥ 8 
S ≤ 0.5; I = 1 - 2; R ≥ 4 
Table 3.1a. Antimicrobial susceptibility testing in host-mimicking media (Staphylococcus)
Spectinomycin MIC (µg/mL)
Clinical Breakpointsa:
Chloramphenicol MIC (µg/mL)
Clinical Breakpointsa:
S ≤ 16; I = 32; R ≥ 64
Clindamycin MIC (µg/mL)
Cephalothin MIC (µg/mL) Ceftiofur MIC (µg/mL)
S ≤ 2; I = 4; R ≥ 8164
S ≤  8; I = 16; R ≥ 32165
Clinical Breakpoints: S ≤ 0.25; R ≥ 0.
Streptomycin MIC (µg/mL) Kanamycin MIC (µg/mL)
Florfenicol MIC (µg/mL)
Clinical Breakpoints:
Ceftriaxone MIC (µg/mL)
S ≤ 8; I =16-32; R ≥ 64163S ≤ 8; I = 16; R ≥ 32163
S ≤ 0.25; R ≥ 0.5163
Daptomycin MIC (µg/mL)
S ≤ 1; NS ≥ 2
S ≤ 8; R ≥ 16
Ampicillin MIC (µg/mL) Trimethoprim MIC (µg/mL) Co-Trimoxazole MIC (µg/mL)Oxacillin MIC (µg/mL)
S ≤ 2/38; R ≥ 4/76
Gentamicin MIC (µg/mL)
Erythromycin MIC (µg/mL)
S ≤ 2; R ≥ 4
Tetracycline MIC (µg/mL) Azithromycin MIC (µg/mL)Linezolid MIC (µg/mL)
S ≤ 4; I = 8; R ≥ 16 
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Table 2b. Antimicrobial susceptibility testing in host-mimicking media (Streptococcus pneumoniae) 
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Table 2c. Antimicrobial susceptibility testing in host-mimicking media (Salmonella) 
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Table 2d. Antimicrobial susceptibility testing in host-mimicking media (Escherichia coli) 
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Table 2e. Antimicrobial susceptibility testing in host-mimicking media (Yersinia pseudotuberculosis)  
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Table 2f. Antimicrobial susceptibility testing in host-mimicking media (Misc Gram-negative)  
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Figure 2. Comparison summary of MICs derived from host-mimicking media 
versus standard MHB medium. (a) Colored regions depict the fraction of 
pathogen-antibiotic combinations tested that exhibited a fold-change in MICs 
(increased susceptibility or resistance) when derived in host-mimicking media 
(DMEM, MLM, LPM pH 5.5) relative to standard MHB medium (test/standard 
condition); ≤2-fold (green), 4-fold (yellow), ≥8-fold (red). (b) Depicted are 
percentages of pathogen-antibiotic combinations that resulted in altered MICs that 
crossed clinical breakpoint designations, used to define isolates as susceptible 
(“S”), intermediate (“I”), or resistant (“R”), that can impact clinical decision making 
on appropriate antibiotic therapy (Clinical and Laboratory Standards Institute, 
2012a; European Committee on Antibiotic Susceptibility Testing, 2014). 
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Figure 3. Antibiotic susceptibility testing in host-mimicking media improves 
the predictive value of AST in the assignment of appropriate antibiotic 
therapy in murine models of sepsis. Pathogen-antibiotic combinations that 
exhibited altered MICs in host-mimicking media relative to standard MHB medium 
and whose MICs crossed clinical breakpoint designations were evaluated in murine 
sepsis models of (a) S. aureus (MRSA [USA300]; MSSA Wound [MT3307]; MRSA 
Blood [MT3302]); (b) S. pneumoniae (SPN Daw25); and (c) S. Typhimurium (ST 
14028) and K. pneumoniae (KPN ATCC13883). (d) MSSA (MT3307) clearance 
from blood circulation was examined following treatment with antibiotics predicted 
as highly effective via testing in standard MHB medium (co-trimoxazole, open 
boxes) or tissue culture medium (DMEM) (azithromycin, closed boxes), 
respectively. Untreated mice (open circles); expired mice (gray region); Colony 
Forming Units (CFU); Limit of Detection (LOD) = 100 CFU/ml (Patterson et al., 
2013). Ten mice were evaluated per cohort. ***P < 0.001, **P < 0.01, or *P < 0.05. 
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Figure 4. Supplementation of standard MHB medium with physiological levels 
of NaHCO3 improves the predictive value of AST in the assignment of 
appropriate antibiotics for therapeutic intervention. (a) S. aureus exhibiting at 
least an 8-fold change in MIC in tissue culture medium (DMEM) vs. MHB medium 
were subjected to susceptibility tests in the presence and absence of physiological 
levels of NaHCO3. Values represent MIC fold-change when derived in MHB medium 
in the presence/absence of NaHCO3 (test/standard condition; left of slash); and in 
DMEM medium in the absence/presence of NaHCO3 (test/standard condition; right 
of slash). Increased susceptibility is depicted in blue; increased resistance is 
depicted in red. Stippled boxes represent those that exhibited <8-fold altered 
susceptibility between MHB and DMEM media. To control for pH and buffer 
considerations, strains were grown in MHB pH 7.2; MHB adjusted to pH 7.2 w/100 
mM Tris; and DMEM liquid pH 7.4 (containing 44 mM NaHCO3); all other media 
conditions were adjusted to pH 7.4 with 100 mM Tris including: MHB w/NaHCO3; 
and NaHCO3-free powdered DMEM w/wo NaHCO3 (Table 3a). (b) Dose response 
analysis of MRSA (USA300; MT3302) and MSSA (MT3307) antibiotic susceptibility 
following exposure to increasing concentrations of NaHCO3 in standard MHB 
medium. AZM (azithromycin); ERY (erythromycin); CFX (ceftriaxone). (c) 
Susceptibility of S. pneumoniae and Salmonella spp. in the presence/absence of 
   
  36 
 
physiological levels of NaHCO3 in MHB and/or DMEM media. For S. pneumoniae, 
values represent fold-change between MICs derived in MHB medium in the 
presence/absence of NaHCO3 (test/standard condition). For Salmonella spp. values 
represent fold-change between MICs derived in MHB medium in the 
presence/absence of NaHCO3 (test/standard condition; left of slash); and DMEM in 
the absence/presence of NaHCO3 (test/standard condition; right of slash). No 
change (NC), Resistant (R). MICs were a consensus of at least 6 independent 
isolates. 
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Table 3a. Antimicrobial susceptibility test in media w/ and w/o NaHCO3 
(Staphylococcus) 
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Table 3b. Antimicrobial susceptibility test in media w/ and w/o NaHCO3 
(Streptococcus) 
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Table 3c. Antimicrobial susceptibility test in media w/ and w/o NaHCO3 
(Salmonella) 
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Chapter 3: Supplementing test media with bicarbonate or fetal bovine serum 
results in changes to antimicrobial susceptibility 
3.1 Introduction  
Bacteria have developed complex signal transduction systems which enable 
them to alter gene expression in response to various environmental cues. Sodium 
bicarbonate (NaHCO3) is an abundant ionic factor found in mammalian tissues that 
stimulates changes in bacterial structure, membrane permeability, and/or gene 
expression (Dorschner et al., 2006). Sodium bicarbonate-induced global changes to 
bacteria resulted in changes in susceptibility to antimicrobial peptides, as shown by 
altered AST results when bicarbonate was added to standard MHB or removed from 
tissue culture medium (Ersoy et al., 2017). Sodium bicarbonate further proved to be 
a host-mimicking signal for a wide variety of strains for several drugs, as shown by 
the fact that susceptibility profiles obtained from NaHCO3-supplemented media 
more accurately predicted the in vivo response than those obtained with the 
standard MHB (Ersoy et al., 2017). Here, we screened all other strains for altered 
resistance to antibiotics when the standard MHB testing medium was supplemented 
with sodium bicarbonate. 
In addition to sodium bicarbonate, components of fetal bovine serum (FBS) play 
a role in signal transduction in many cell types, whether it be desensitizing a 
receptor, inducing protein translocation, or causing cytokine release in 
macrophages during bacterial infection (Berenguer, Martinez, Giorgetti-Peraldi, Le 
Marchand-Brustel, & Govers, 2010; Brar et al., 1999; Chrisman, Perkins, & Garbers, 
2003; Flesch & Kaufmann, 1999; Wang, Maier, Wenz, Giordano, & Herskind, 2013). 
Since serum factors have been shown to be functionally involved in many 
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processes, we had reason to believe that the addition of FBS to host-mimicking 
media for AST testing would lead to changes in a strain’s resistance or susceptibility 
to a drug. We screened a subset of drugs for 10 Staphylococcus strains and 5 E. 
coli strains, using tissue culture medium, Dulbecco’s Modified Eagle Medium 
(DMEM), supplemented with various levels of FBS as the testing media. 
3.2 Results 
3.2.1 Addition of NaHCO3 to standard MHB medium affects antimicrobial 
susceptibility 
We completed MIC testing in MHB supplemented with NaHCO3, for all strain 
and drug combinations that had not been previously determined as described in 
Ersoy et al. (2017; chapter 2). These included Staphylococcus spp., Streptococcus 
pneumoniae, and Gram-negative strains. Four categories were identified which 
describe the possible breakpoint changes resulting from addition of NaHCO3 to the 
standard MHB (Table 4): 1) MICs performed in MHB vs DMEM have different 
breakpoints and adding NaHCO3 to MHB results in the same breakpoint as DMEM; 
2) MICs performed in MHB and DMEM have the same breakpoint and adding 
NaHCO3 to MHB changes this breakpoint; 3) MICs performed in MHB vs DMEM 
have different breakpoints and adding NaHCO3 to MHB results in the same 
breakpoint as MHB; and 4) MICs performed in MHB and DMEM have the same 
breakpoint and adding NaHCO3 to MHB does not change this breakpoint. In 
categories 1 and 2, MHB supplemented with NaHCO3 yields differing breakpoints 
than the standard MHB used for AST testing, indicating an effect of sodium 
bicarbonate on antimicrobial susceptibility. Interestingly, category 1 findings 
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demonstrate the possibility of obtaining the same breakpoint designations obtained 
by host-mimicking media by simply adding a signal-inducing molecule to the 
standard MHB media. In categories 3 and 4, sodium bicarbonate did not change the 
breakpoint when added to standard MHB. 
Staphylococcus 
Staphylococcus strains grown in MHB supplemented with NaHCO3 
(MHB+NaHCO3) demonstrated trends of increased susceptibility to azithromycin 
and erythromycin and increased resistance to nalidixic acid (Fig. 5a, (Ersoy et al., 
2017)). However, these large fold-changes in MIC values between MHB and 
MHB+NaHCO3 did not cross clinical breakpoints (Table 5a).  
Category 1 consists of instances where supplementing standard MHB with 
NaHCO3 resulted in a breakpoint that resembled the DMEM breakpoint and differed 
from the MHB breakpoint. For example, MRSA USA300 and cephalothin 
demonstrated a shift from the “R” breakpoint in MHB to the “S” breakpoint seen in 
both MHB+NaHCO3 and DMEM (Table 1), categorizing this drug and strain 
combination as Category 1. New findings include clinical breakpoint changes 
showing increased susceptibility of MSSA Urine (R to S) and MSSA Sputum (R to I) 
to streptomycin, as well as increased resistance of MSSA Urine (S to I) to 
tetracycline, when NaHCO3 was added to MHB (Table 4a, Table 5a).  
Category 2 portrays instances where addition of NaHCO3 to MHB results in a 
clinical breakpoint that is different than the breakpoint shared by MHB and DMEM. 
For example, MSSA Blood, MSSA Wound, and MSSA Urine are “Susceptible” to 
ceftiofur in MHB and DMEM, but “Intermediate” to ceftiofur in MHB+NaHCO3 (Table 
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4a, Table 5a). Even more significant is the shift in clinical breakpoints seen in 
MSSA Wound and MSSA Urine, which are “Susceptible” to ampicillin in MHB and 
DMEM, but “Resistant” to ampicillin when MHB is supplemented with NaHCO3. 
Lastly, MSSA Urine shows increased resistance to ceftriaxone (S to I) with the 
addition of NaHCO3 to MHB.  
Streptococcus pneumoniae 
All 6 Streptococcus pneumoniae strains grown in MHB + NaHCO3 showed 
significantly increased susceptibility (16- or 32-fold) to azithromycin compared to 
those grown in MHB ((Ersoy et al., 2017), Fig. 5b), but these large fold changes did 
not cross clinical breakpoints (Table 5b). Conversely, a small 2-fold change in MIC 
values between MHB and MHB+NaHCO3 resulted in breakpoint changes for Daw 
25 (R to S, trimethoprim) and Daw 2 (R to I, co-trimoxazole). Additionally, Daw 1 
was “Susceptible” to ceftriaxone in MHB and DMEM, but “Intermediate” to 
ceftriaxone in MHB+NaHCO3, with a 4-fold change in MIC value between MHB and 
MHB+NaHCO3. 
Gram-negative Bacteria 
Trends of increased susceptibility (8- to 64-fold) to azithromycin and 
erythromycin were seen among Salmonella and Escherichia coli (E. coli) strains 
when NaHCO3 was added to MHB (Fig. 5c). Increased susceptibility (8- or 16-fold) 
to azithromycin in MHB+NaHCO3 was also found for Providencia stuartii, 
Citrobacter freundii, and Pseudomonas aeruginosa. Providencia stuartii changed 
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breakpoints from “R” in MHB to “S” in MHB+NaHCO3 when tested with azithromycin 
(Table 4c). 
Additionally, trends of increased resistance (4- or 8-fold) were seen among E. 
coli strains to ampicillin, nalidixic acid, and enrofloxacin (Fig. 5c). While no changes 
in breakpoint between MHB and MHB+NaHCO3 were found with nalidixic acid, 
breakpoint changes were observed for ampicillin and enrofloxacin. Citrobacter 
freundii (I to R) and E. coli strains ATCC 25922 (S to I), UPEC J96 (S to R), UPEC 
ECR12 (S to I), UPEC ATCC 11775 (S to I), APEC χ7126 (S to I), A96 χ7117 (S to 
R), EPEC χ2927 (S to R), and RDEC-1 χ2862 (S to R) all showed increased 
resistance to ampicillin when NaHCO3 was added to MHB. Similarly, E. coli strains 
EPEC χ2927, UPEC J96, UPEC ECR12, and EPEC JPN 15 all indicated increased 
resistance to enrofloxacin as shown by an “S” to “I” change in clinical breakpoints 
with NaHCO3 addition to MHB. 
3/4 Yersinia strains tested showed an 8- or 16-fold increase in resistance to 
tetracycline, and these changes crossed clinical breakpoints (S to R; S to I) (Table 
4c, Table 5c). Additionally, the Salmonella strain S. Dublin displayed an “R” 
breakpoint in MHB and an “S” breakpoint in MHB+NaHCO3 when tested with 
Polymyxin B (16-fold MIC change) and Colistin Sulfate (8-fold MIC change). 
3.2.2 Addition of fetal bovine serum (FBS) to tissue culture medium affects 
antimicrobial susceptibility 
To further test for possible changes in antimicrobial susceptibility resulting from 
the presence of extracellular signals, we investigated the effects of fetal bovine 
serum (FBS) on AST results for Staphylococcus strains and Gram-negative strains 
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in response to a selection of drugs. Since FBS is known to induce a variety of 
signals in different cell types, we supplemented tissue culture medium, Dulbecco’s 
Modified Eagle Medium (DMEM), with increasing concentrations of fetal bovine 
serum (FBS) to test for changes in antimicrobial susceptibility compared to DMEM 
alone or MHB alone.  
Staphylococcus 
7/10 Staphylococcus strains grown in DMEM supplemented with FBS (DMEM + 
FBS) show increased resistance to ceftiofur compared to DMEM alone or MHB 
alone (Fig. 6a). MSSA Blood, MSSA Wound, MSSA Urine, MSSA Sputum, CoN S. 
lugdunensis, CoN S. epidermidis, and CoN S. warneri show increased resistance to 
ceftiofur in a dose-dependent manner, as shown by the gradual increases in 
resistance as the percentage of FBS in DMEM increases (Table 6a). Further, these 
7 Staphylococcus strains undergo changes in clinical breakpoints with the addition 
of FBS to DMEM. For example, MSSA Blood is “Susceptible” to ceftiofur in DMEM 
with 0% FBS, “Intermediate” in DMEM supplemented with either 5% or 10% FBS, 
and “Resistant” to ceftiofur in DMEM supplemented with either 20% or 50% FBS. 
Additionally, CoN S. warneri is “Susceptible” to ceftiofur in DMEM supplemented 
with 0%, 5%, 10%, or 20% FBS, and “Intermediate” in DMEM supplemented with 
50% FBS. 
Dose-dependent changes in MIC values and clinical breakpoints in response to 
FBS is also seen with MSSA Sputum and chloramphenicol (Table 6a). MSSA 
Sputum is “Susceptible” to chloramphenicol in DMEM with 0%, 5%, and 10% FBS, 
“Intermediate” in DMEM with 20% FBS, and “Resistant” to chloramphenicol in 
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DMEM with 50% FBS. Various other Staphylococcus strains (MRSA USA300, 
MRSA Wound, MSSA Blood, MSSA Wound, MSSA Urine, CoN S. epidermidis, and 
CoN S. warneri) also seem to respond to the increased FBS in DMEM as shown by 
2-fold increases in resistance to chloramphenicol that cross clinical breakpoints (S 
to I; I to R). 
Gram-negative bacteria 
2/5 Gram-negative strains tested (S. Typhimurium 14028, E. coli strain APEC 
χ7126) showed 4-fold increases in resistance to nalidixic acid from DMEM + 0% 
FBS to DMEM + 50% FBS (Fig. 6b). For S. Typhimurium 14028, this increase in 
resistance to nalidixic acid crossed a clinical breakpoint as the strain is 
“Susceptible” in DMEM with 0%, 5%, 10%, and 20% FBS, but “Resistant” in DMEM 
with 50% FBS (Table 6b).  
There are no defined clinical breakpoints for S. Typhimurium 14028 in 
erythromycin, but the strain undergoes a seemingly dose-dependent increase in 
resistance, as shown by the MIC value of 32µg/mL in DMEM with 0% FBS, 
64µg/mL in DMEM with 5% and 10% FBS, and 128µg/mL in DMEM with 20% and 
50% FBS (Table 6b). Additionally, S. Typhimurium TY1212 undergoes a 4-fold 
increase in susceptibility to ceftiofur from DMEM with 0% FBS to DMEM with 5%, 
10%, 20%, and 50% FBS, without crossing any breakpoints. 
While only a 2-fold change in the MIC value, S. Typhimurium 14028 crosses a 
breakpoint (S to I) such that the strain is “Susceptible” to spectinomycin in DMEM 
with 0%, 5%, and 10% FBS, but “Intermediate” in DMEM with 20% and 50% FBS. 
Similarly, E. coli strain APEC χ7126 undergoes a 2-fold increase in resistance to 
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chloramphenicol, changing the breakpoint from “Susceptible” in DMEM with 0%, 
5%, and 10% FBS to “Intermediate” in DMEM with 20% and 50% FBS. Lastly, a 2-
fold increase in resistance of S. Typhimurium TY1212 to nalidixic acid shifts the 
“Susceptible” breakpoint in DMEM with 0%, 5%, and 10% FBS to “Resistant” in 
DMEM with 20% and 50% FBS.  
3.3 Discussion 
Overall, there are several instances of changes in clinical breakpoints resulting 
from addition of either NaHCO3 or FBS to media. These changes in clinical 
breakpoints indicate that caution should be taken when prescribing the antibiotic for 
that infection. Further, these changes reveal the risk of testing in a single media 
because crucial information that may change the treatment decision will be missed. 
If testing in multiple media was implemented in clinical settings, it would enable 
multiple susceptibility profiles to be gathered and compared, whereas the current 
standard AST testing only provides a single MIC value and breakpoint designation. 
Further, when clinical breakpoint changes are observed between two testing media, 
additional signal-inducing media should be included in the analysis of the strain’s 
susceptibility to that drug. Additionally, in vivo mouse experiments should be 
conducted to investigate the accuracy of the AST results presented in this thesis 
and the ability of the “host-mimicking” media to truly represent the host 
environment. Although in vivo experiments would not be able to follow the often 
rushed timeline of clinical testing, they have been shown to support the 
susceptibility profiles obtained when AST was performed in host-mimicking media. 
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There are also several cases of large fold changes between MIC values 
obtained from the standard media versus the alternative media, but they do not 
cross clinical breakpoints. However, since these instances are clearly affected by 
extracellular signals, they should be further investigated in different host-mimicking 
media. On the other hand, there are cases where a small 2-fold change in MIC 
values crosses a clinical breakpoint. Two-fold differences in MIC values are 
generally considered to be insignificant. However, in these cases, we should be 
aware that the MIC value is on the cusp of its clinical breakpoint designation and 
thus a simple change in testing media may hold a greater weight on its AST 
susceptibility profile. 
It is also important to recognize that in some cases the gradual changes in MIC 
values between 0%-50% FBS seem to be dose-dependent. In these cases 
especially, testing with an increased percentage of FBS (50-100%) may further 
increase the 2-fold change and possibly even change the clinical breakpoint. These 
findings imply that testing with greater percentages of FBS may lead to greater 
changes in MIC values and possibly changes in breakpoints as well. 
While not every drug and strain combination demonstrates a breakpoint change 
or significant fold-change between standard MHB and alternative media, it has been 
made clear that AST results often vary – and possibly even improve – with the 
presence of signaling molecules in the testing media. Current AST testing does not 
allow for these discoveries as only one standard media is used to make a decision 
on the antibiotic to prescribe. A greater variety of testing media that can be used for 
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AST testing would enable more data and more informed decisions on the best drug 
to treat infections with. 
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Figures 
Table 4. Adding NaHCO3 to MHB media results in MICs that cross clinical 
breakpoint designations which advise on patient therapy. Depicted are 
instances of clinical breakpoint changes resulting from the addition of 44mM 
NaHCO3 to standard MHB, for (a) Staphylococcus spp., (b) Streptococcus 
pneumoniae, and (c) Gram-negative bacteria. 
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Figure 5. Fold change comparison of MIC values in MHB supplemented with 44mM NaHCO3, relative to standard 
MHB. A panel of antibiotics was screened for changes in MIC values for (a) Staphylococcus spp., (b) Streptococcus 
pneumoniae, and (c) Gram-negative bacteria. Values depict the fold-change in MICs when AST was performed in MHB 
supplemented with 100mM Tris buffer and 44mM NaHCO3, relative to standard MHB. Fold changes listed as “Not 
Applicable” (NA) were disregarded due to an effect of Tris buffer on antimicrobial susceptibility. MIC values were obtained 
from at least 6 independent determinations 
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Table 5a. Antimicrobial susceptibility test in media w/ NaHCO3 (Staphylococcus) 
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Table 5b. Antimicrobial susceptibility test in media w/ NaHCO3 (Streptococcus pneumoniae) 
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Table 5c. Antimicrobial susceptibility test in media w/ NaHCO3 (Gram-negative bacteria) 
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Figure 6. Fold change comparison of MIC values in DMEM supplemented with 
increasing concentrations of fetal bovine serum (FBS), relative to standard 
MHB. A panel of antibiotics was screened for changes in MIC values for (a) 
Staphylococcus spp. and (b) Gram-negative bacteria. Ca-MHB MIC values are 
shown. FBS values depict the fold-change in MICs when AST was performed in 
DMEM supplemented with 0%, 5%, 10%, 20%, and 50% FBS, relative to standard 
MHB. MIC values were obtained from at least 6 independent determinations. 
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Table 6a. Antimicrobial susceptibility test in media supplemented with FBS (Staphylococcus) 
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Table 6b. Antimicrobial susceptibility test in media supplemented with FBS (Gram-negative bacteria) 
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Chapter 4: Conclusions and Future Directions 
The antibiotic crisis is a global threat and must be made a priority for research 
and clinical settings. While measures such as vaccination and hygienic practices 
are in place to reduce the spread of infection disease, infectious disease is still 
among the top 10 causes of death worldwide (Centers for Disease Control and 
Prevention, 2011). To help resolve this ongoing problem, we investigated novel 
methods to improve the accuracy of antimicrobial susceptibility testing and thus 
encourage proper use of antimicrobials and reduce instances of antibiotic 
resistance. 
In Chapter 2, the antimicrobial susceptibility profiles of pathogenic bacteria were 
investigated in various host-mimicking media to provide a more thorough 
understanding of the scope of altered susceptibility. We hypothesized that due to 
the different environmental signals in host-mimicking media compared to MHB, 
levels of antimicrobial resistance would significantly differ between media. 
Additionally, we predicted that the susceptibility profiles obtained in host-mimicking 
media would be more representative of an in vivo infection. We discovered that 
there were several instances of drugs showing high levels of resistance in host-
mimicking media that showed susceptibility in MHB and therefore may have 
incorrectly been considered as a valid treatment option. Alternatively, we found that 
certain strains were susceptible to a particular drug in host-mimicking media but 
found to be resistant in MHB, implying that they were susceptible to drugs that 
would have otherwise been excluded as a treatment option. Importantly, many of 
the predicted susceptibility profiles in host-mimicking media were proven accurate in 
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animal testing models and therefore contradicted values obtained with the standard 
MHB. Also in Chapter 2 we introduced NaHCO3 as a signaling molecule that 
influenced antimicrobial susceptibility. In several cases, the susceptibility profile 
obtained with host-mimicking media was observed by adding NaHCO3 to MHB. 
Although this method could not be applied to every strain in every case, it is a 
helpful step in expanding the possibilities of in vitro testing to better predict 
treatment outcomes. 
In Chapter 3, we completed the screening of the NaHCO3 data described in 
Chapter 2 to better understand the scope of the effect of sodium bicarbonate on 
antimicrobial susceptibility. In addition, we investigated the antimicrobial 
susceptibility profiles that resulted from supplementing media with fetal bovine 
serum (FBS). We hypothesized that supplementing host-mimicking media with 
various levels of FBS would create susceptibility profiles that not only differed from 
MHB, but also would display a dose response to the levels of FBS. We discovered 
that supplementing host-mimicking media with FBS further led to susceptibility 
profiles that significantly differed from those obtained with MHB. Additionally, dose-
dependent responses were observed in some cases as the susceptibility gradually 
increased or decreased with the change in %FBS. Overall these results 
demonstrated that signals in the extracellular environment clearly play a role in the 
bacteria’s signaling process in a way can alter their susceptibility to a given drug. 
Ultimately, our findings suggest that the results of AST are often dependent on 
the presence of certain signals found in the extracellular environment. Therefore, it 
should be recognized that utilizing the optimal host-mimicking media for a particular 
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strain is necessary to obtain accurate AST results. Since there is no single media 
that will provide accurate test results for all strains in every case, MIC testing should 
be conducted using multiple testing media containing signals that may be 
encountered by the given pathogenic strain in the host environment. This would 
provide valuable insight into the commonly contradicting MIC values obtained 
between host-mimicking and standard media, and this knowledge would be well 
worth the additional cost to routinely complete these experiments. As explained 
previously, incorrect prescription of drugs leads to selection of resistant bacteria and 
inability to improve the patient’s condition. Accurate AST results and proper use of 
antibiotics is crucial in helping solve the antibiotic resistance crisis. Therefore, by 
performing AST in multiple host-mimicking media alongside MHB, we obtain more 
information to support the decision of which drug to treat with. 
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Chapter 5: Materials and Methods 
†This chapter contains excerpts, reproduced with permission, from Ersoy SC et 
al. (2017) Correcting a Fundamental Flaw in the Paradigm for Antimicrobial 
Susceptibility Testing. EBioMedicine. (20): 173-181. 
5.1 Bacterial Strains and Media 
Staphylococcal clinical isolates analyzed included USA300, a community-
associated methicillin-resistant Staphylococcus aureus (SA) isolate causing the 
most MRSA infections in the United States (Diekema et al., 2014); and 9 isolates 
from human sepsis patients (Santa Barbara Cottage Hospital, 2016) with various 
host sites of pathogen origin including blood, wound, urine, sputum (termed MRSA 
Blood [MT3302]; Wound [MT3315]); MSSA (Blood [MT3305]; Wound [MT3307]; 
Urine [MT3309]; Sputum [MT3314]); and CoNS (S. epidermidis, blood [MT3320]; S. 
lugdunensis, blood [MT3317]; S. warneri, blood [MT3321]). S. pneumoniae (SPN) 
clinical isolates included D39 (ser. 2) (Lanie et al., 2007), and 5 SPN isolates 
derived from the nasopharynx of children with sickle cell anemia at risk for invasive 
pneumococcal disease (Daw 1 [serotype 6]; Daw 2 [serotype 23]; Daw 19 [serotype 
6]; Daw 20 [serotype 11]; Daw 25 [serotype 35C]) (Carter et al., 2014; Daw et al., 
1997). Gram-negative bacterial isolates included Salmonella spp., Salmonella 
Typhimurium ATCC 14028, TY1212; and var. 5 (04)-9639; S. Dublin Lane; S. 
Newport (03)-721; S. Choleraesuis χ3236 (Heithoff et al., 2012; Heithoff et al., 
2008); E. coli ATCC 25922; UPEC J96; UPEC ECR12; UPEC ATCC 11775; APEC 
χ7126; A96 χ7117; EPEC χ2927); RDEC-1 χ2862; EPEC JPN 15; Yersinia 
pseudotuberculosis (YPIII/pIB1; IP32953; IP2515; IP2666) (Kubicek-Sutherland, 
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Heithoff, Ersoy, Shimp, & Mahan, 2014); Shigella flexneri ATCC 29903; Providencia 
stuartii ATCC 29914; Citrobacter freundii ATCC 8090; Klebsiella pneumoniae ATCC 
13883; Pseudomonas aeruginosa ATCC 10145. All Staphylococcus strains were 
isolated on Tryptic Soy Broth Agar (TSA) incubated at 37 °C in ambient air. S. 
pneumoniae strains were isolated on Columbia Sheep's Blood Agar (CSBA) and 
grown in Todd-Hewitt Broth (THB) supplemented with 2% yeast extract incubated at 
37 °C in a 5% CO2 incubator. Gram-negative bacteria were isolated on Luria-
Bertani (LB) agar (Davis, 1980) incubated at 37 °C or 28 °C (Yersinia) in ambient 
air. Standard AST broth medium is Mueller–Hinton Broth (MHB) supplemented with 
CaCl2 and MgCl2 to make cation-adjusted MHB (Ca-MHB) (Clinical and Laboratory 
Standards Institute, 2012a). AST was also performed in Dulbecco's Modified Eagle 
Medium (DMEM (Dulbecco & Freeman, 1959); High Glucose [Life Technologies]); 
Lacks medium (Lacks, 1966); modified Lacks medium (MLM) (Hathaway et al., 
2012); low phosphate, low magnesium medium (LPM) (Coombes et al., 2004); and 
Fetal Bovine Serum (FBS; qualified, USDA-approved regions [Life Technologies]). 
DMEM and FBS cultures were incubated in a 5% CO2 incubator; all other conditions 
were incubated in ambient air. To facilitate growth, DMEM was supplemented with 
5% LB broth for Staphylococci, and 5% Lysed Horse Blood (LHB) for S. 
pneumoniae; MLM was supplemented with 5% THB for S. pneumoniae D39. 
5.2 MIC Assays 
The minimum inhibitory concentration (MIC) was determined according to the 
Clinical and Laboratory Standards Institute (CLSI) guidelines by either broth or agar 
dilution (Clinical and Laboratory Standards Institute, 2012a; Wiegand et al., 2008). 
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For determination of MIC in alternative media conditions, bacteria were obtained 
from overnight culture (Staphylococci and Gram-negative bacteria) or after a 4 h 
incubation period (S. pneumoniae) in specified medium and diluted into same 
medium containing 2-fold serial dilutions of antibiotics. To control for the potential 
effects of pH and media composition for LPM pH 5.5 comparisons, antibiotic 
resistance and clinical breakpoint designations were calculated by comparing the 
MIC in LPM medium divided by the MIC in MHB medium at both pH 5.5 and pH 7 
(unbuffered) (ratio of LPM pH 5.5/pH 7.0 to MHB pH 5.5/pH 7.2) (Kubicek-
Sutherland et al., 2015). MIC values were derived after 20 h incubation, and were 
the result of at least 6 independent determinations. 
5.3 Sodium Bicarbonate Susceptibility Assays 
Strains were grown in MHB pH 7.2; unbuffered; MHB adjusted to pH 7.2 with 
100 mM Tris(hydroxymethyl)aminomethane (Fisher Scientific); and DMEM liquid pH 
7.4 (containing 44 mM NaHCO3; Difco/Becton Dickinson). All other media conditions 
were adjusted to pH 7.4 with 100 mM Tris including: MHB medium w/NaHCO3; and 
NaHCO3-free powdered DMEM w/wo NaHCO3. Bacteria were grown overnight in 
specified medium and diluted as described above. For S. pneumoniae isolates, 
NaHCO3 assays were performed in MHB medium in the CO2 incubator due to 
viability considerations since S. pneumoniae isolates tested did not grow in either 
MHB medium with NaHCO3 in ambient air; or in DMEM in the absence of NaHCO3 
in the CO2 incubator. MIC values were the result of at least 6 independent 
determinations completed on at least two days. Control MICs in MHB or DMEM 
were always performed alongside the experimental media conditions. 
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5.4 Virulence Assays 
5.4.1 Intraperitoneal (i.p.) Infection 
S. Typhimurium 14028 (dose of 102 CFU) and S. pneumoniae Daw 25 (dose of 
9 × 107 CFU) were grown overnight in LB or Todd-Hewitt medium with 2% yeast 
extract, respectively, and sub-cultured to A600 = 0.4, resuspended in 0.15 M NaCl, 
and administered to mice via the i.p. route of infection. 
5.4.2 Intravenous (i.v.) Infection 
MRSA USA300 (dose 1 × 108 CFU), MRSA Blood (MT3302; dose 1.5 × 108 
CFU) and MSSA Wound (MT3307; dose of 2 × 108 CFU) were grown overnight in 
TSB and sub-cultured to A600 = 0.4; and K. pneumoniae ATCC 13883 (dose of 2 × 
108 CFU) were grown overnight in LB medium. Strains were resuspended in 0.15 M 
NaCl and administered i.v. to mice by retro-orbital injection. 
5.4.3 Antibiotic Treatment 
Infected mice were treated (or mock-treated) with the following dosing regimens 
beginning 2 h post-infection: azithromycin (100 mg/kg/day), ceftiofur (40 mg/kg/day), 
ceftriaxone (50 mg/kg/day), cephalothin (200 mg/kg/day), ciprofloxacin (30 
mg/kg/day), colistin (30 mg/kg/day), co-trimoxazole (15 mg/kg/day), daptomycin (10 
mg/kg/day), erythromycin (100 mg/kg/day), tetracycline (100 mg/kg/day), or 
trimethoprim (30 mg/kg/day). 
5.4.4 Bacterial Clearance 
Mice infected with MSSA Wound (MT3307; dose of 4 × 108 CFU) were treated 
with azithromycin or co-trimoxazole. All drug doses were delivered once every 24 h 
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except cephalothin, ciprofloxacin, colistin, and co-trimoxazole, which were delivered 
once every 12 h; ceftriaxone and ceftiofur were given every 12 h for MRSA Blood 
(MT3302) experiments. All drugs were delivered by the i.p. route with the exception 
of cephalothin (subcutaneous). Mouse survival was assessed for 10 days post-
infection. Equal numbers of male and female 10- to 12- week-old litter-mate 
C57BL/6J mice were used in all virulence studies. Institutional Animal Care and Use 
Committee of the University of California, Santa Barbara approved all mouse 
research protocols undertaken herein. 
5.5 Statistical Analysis 
Statistical significance for difference in proportions of animal survival was 
calculated using Chi-square (Epi Info 7, CDC). For all statistical analyses, a 
significance level (P) of <0.05 was considered to be statistically significant. Degrees 
of statistical significance are presented as ***P < 0.001, **P < 0.01, or *P < 0.05.  
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